Although antibodies targeting proteins at the node and paranode of Ranvier, such as NF155, CNTN1, Caspr1, NF186, and NF140, were first described in a small subgroup of patients with CIDP, the immunopathological mechanisms of patients with these antibodies were largely related to the disruption of the nodal or paranodal region structure, which was different from the peripheral nerve demyelination in typical CIDP (3). The gene discussed is CNTNAP1; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.